# Kardigan, Inc.: overview KARD · Nasdaq · CIK 2123613 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/kard.md) · [Financials](/companies/kard/financials.md) · [Filings](/companies/kard/filings.md) · [Insiders](/companies/kard/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(4.64)](/filings/0001193125-26-343418.md) | not reported | [(4.61)](/filings/0001193125-26-343418.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL not reported. ## Last five fiscal years Not reported. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kard/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [HRTG GPE, LLC](/funds/1537455.md) | 2026-06-30 | $403.5m | 16,917,034 | | New +16,917,034 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $212.5m | 8,909,066 | | New +8,909,066 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $195.6m | 8,200,662 | | New +8,200,662 | | [Capital Research Global Investors](/funds/1422848.md) | 2026-06-30 | $85.8m | 3,598,942 | | New +3,598,942 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $46.4m | 1,790,734 | | New +1,790,734 | | [ALLIANCEBERNSTEIN L.P.](/funds/1109448.md) | 2026-06-30 | $36.6m | 1,534,837 | | New +1,534,837 | | [Liberty Mutual Group Asset Management Inc.](/funds/1533497.md) | 2026-06-30 | $28.5m | 1,196,411 | | New +1,196,411 | | [JENNISON ASSOCIATES LLC](/funds/53417.md) | 2026-06-30 | $21.6m | 903,575 | | New +903,575 | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $21.5m | 900,000 | | New +900,000 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $17.7m | 749,703 | | Not compared | ## Recent filings [All 54 filings](/companies/kard/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-01 | 20:35 ET | [SCHEDULE 13D/A](/filings/0001193125-26-410754.md) | Ownership report, active investor, amended | 0001193125-26-410754 | | 2026-09-30 | 12:01 ET | [8-K](/filings/0001193125-26-408348.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-408348 | | 2026-08-11 | 11:10 ET | [10-Q](/filings/0001193125-26-343418.md) | Quarterly report, period 2026-06-30 | 0001193125-26-343418 | | 2026-08-11 | 11:00 ET | [8-K](/filings/0001193125-26-343395.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-343395 | | 2026-06-29 | 20:05 ET | [SCHEDULE 13D](/filings/0001193125-26-288406.md) | Ownership report, active investor | 0001193125-26-288406 | | 2026-06-25 | 20:00 ET | [SCHEDULE 13D](/filings/0001193125-26-282713.md) | Ownership report, active investor | 0001193125-26-282713 | | 2026-06-23 | 10:05 ET | [8-K](/filings/0001193125-26-278429.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-278429 | | 2026-06-11 | 10:16 ET | [S-1/A](/filings/0001193125-26-266629.md) | Registration statement, amended | 0001193125-26-266629 | | 2026-05-26 | 20:13 ET | [S-1](/filings/0001193125-26-239298.md) | Registration statement | 0001193125-26-239298 | ## Latest annual report No annual report is in coverage. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 2123613 - Tickers: KARD - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.